Evaluation of Subcutaneous (SC) Injected Tc 99m Tilmanocept Localization in Active Rheumatoid Arthritis (RA) Subjects by SPECT and SPECT/CT Imaging
Phase of Trial: Phase I
Latest Information Update: 19 Dec 2016
At a glance
- Drugs Tc 99m tilmanocept (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Navidea Biopharmaceuticals
- 14 Dec 2016 Status changed from recruiting to completed.
- 03 Nov 2016 According to a Navidea Biopharmaceuticals media release, to date, 17 of 18 patients have been dosed and imaged in the study.
- 01 Aug 2016 Status changed from not yet recruiting to recruiting.